Polidocanol: A Review of Off-Label Dermatologic Uses

被引:3
|
作者
Nguyen, Quoc-Bao D. [1 ,2 ]
Stender, Carly [3 ]
Bur, Delfina [3 ]
Silapunt, Sirunya [1 ]
机构
[1] Univ Texas Houston, Dept Dermatol, McGovern Med Sch Houston, 6655 Travis St,Suite 980, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
[3] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
关键词
SODIUM TETRADECYL SULFATE; PROSPECTIVE COMPARATIVE TRIAL; TELANGIECTATIC LEG VEINS; DIGITAL MUCOUS CYSTS; SOFT-TISSUE TUMORS; FOAM SCLEROTHERAPY; DOUBLE-BLIND; DETERGENT SCLEROSANTS; PERIOCULAR VEINS; VARICOSE;
D O I
10.1097/DSS.0000000000003520
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND Polidocanol is an FDA-approved treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, but numerous other off-label dermatological applications have been reported. OBJECTIVE To describe the various off-label dermatological clinical uses of polidocanol, as well as efficacy and adverse effects. METHODS The review of studies searchable on PubMed from 2004 to 2021 describing clinical uses of polidocanol to determine efficacy and adverse effects associated with various dermatologic applications. RESULTS Polidocanol has shown efficacy in the treatment of mucocele of minor salivary gland, hemangioma, upper extremity veins, reticular veins of the chest, facial veins, pyogenic granuloma, lymphangioma circumscriptum, digital mucous cyst, mixed skin ulcers, cutaneous focal mucinosis, seromas, glomuvenous malformations, acne cysts, lymphocele, and dissecting cellulitis. Commonly reported side effects include pain, erythema, swelling, ecchymosis, and ulceration. Most sources were case reports and small prospective studies, as such the strength of data supporting many uses is limited by small sample sizes and lack of controls. CONCLUSION Although polidocanol is currently only FDA approved for incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system, the use of polidocanol has been selected for a variety of off-label clinical applications.
引用
收藏
页码:961 / 966
页数:6
相关论文
共 50 条
  • [1] Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses
    Dai, Annie
    Kim, Soo Jung
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (02) : 358 - 367
  • [2] Off-label dermatologic uses of IL-17 inhibitors
    Wu, Kevin K.
    Dao, Harry, Jr.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 41 - 47
  • [3] Off-label dermatologic uses of anti-TNF-a therapies
    Alexis, Andrew F.
    Strober, Bruce E.
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 (06) : 296 - 302
  • [4] Off-label uses of trazodone: a review
    Bossini, Letizia
    Casolaro, Ilaria
    Koukouna, Despoina
    Cecchini, Federica
    Fagiolini, Andrea
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (12) : 1707 - 1717
  • [5] Ivabradine: A Review of Labeled and Off-Label Uses
    Oliphant, Carrie S.
    Owens, Ryan E.
    Bolorunduro, Oluwaseyi B.
    Jha, Sunil K.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (05) : 337 - 347
  • [6] Ivabradine: A Review of Labeled and Off-Label Uses
    Carrie S. Oliphant
    Ryan E. Owens
    Oluwaseyi B. Bolorunduro
    Sunil K. Jha
    [J]. American Journal of Cardiovascular Drugs, 2016, 16 : 337 - 347
  • [7] A qualitative review of off-label uses of intravenous immunglobulin
    Leong, H.
    Stachnik, J. M.
    Bonk, M. E.
    Matuszewski, K.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A40 - A40
  • [8] Comment on: Ivabradine: A Review of Labeled and Off-Label Uses
    Sébastien Champion
    [J]. American Journal of Cardiovascular Drugs, 2016, 16 : 473 - 474
  • [9] Dupilumab: A Review of Present Indications and Off-Label Uses
    Munoz-Bellido, F. J.
    Moreno, E.
    Davila, I
    [J]. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2022, 32 (02) : 97 - 115
  • [10] Off-Label Uses of Omalizumab
    David El-Qutob
    [J]. Clinical Reviews in Allergy & Immunology, 2016, 50 : 84 - 96